Ochayon Lea, Tunin Rina, Yoselis Aviva, Kadmon Ilana
Radiotherapy Unit and Oncology Clinic, Hadassah Medical Organization, Jerusalem, Israel.
Henrietta Szold Hadassah Hebrew University School of Nursing, Jerusalem, Israel; Hadassah Medical Organization, Jerusalem, Israel.
Eur J Oncol Nurs. 2015 Jun;19(3):260-7. doi: 10.1016/j.ejon.2014.11.003. Epub 2014 Dec 17.
Although there has been a significant reduction in mortality, breast cancer is the most frequent cancer among women worldwide. This decline in mortality has created a significant survivor population that must manage the post curative treatment phase, in order to have an increased quality of life and well-being. This study examined the relationship between symptom interference and severity with the perception of social support in the lives of women receiving or not receiving, hormonal therapy after initial treatment.
Participants completed symptom severity and interference questionnaires, (MDASI and BCPT), a social support survey (MSPSS) and demographic and comorbidity questionnaires.
Of the 210 women participants, higher symptom severity correlated with unemployment, living alone or being religious. Participants who were currently taking hormonal treatment (n = 84), reported a significant negative correlation between symptom severity, measured by MDASI, and social support (p = 0.006). Consequently, as symptom severity increased, perceived social support decreased. In the BCPT assessment, decreased cognitive functioning (p < 0.05), pain (p < 0.05), bladder dysfunction (p = 0.001), and reduced self-image (p < 0.01) were significantly negatively correlated with social support for those participants currently taking hormonal therapy. Participants who had not previously received hormonal therapy (n = 64), cognitive dysfunction and bladder dysfunction were negatively correlated with social support. Women with preexisting heart or pulmonary dysfunction and arthritis reported statistically significant higher levels of symptom severity and decreased perceptions of social support.
Identifying socio-demographic variables and comorbidities that affect hormonal therapy symptom burden is essential for offering adequate support for breast cancer survivors.
尽管死亡率已显著下降，但乳腺癌仍是全球女性中最常见的癌症。死亡率的下降产生了大量的幸存者群体，这些幸存者必须应对治愈后治疗阶段，以提高生活质量和幸福感。本研究调查了在接受或未接受初始治疗后激素治疗的女性生活中，症状干扰和严重程度与社会支持感知之间的关系。
参与者完成了症状严重程度和干扰问卷（MDASI和BCPT）、社会支持调查（MSPSS）以及人口统计学和共病问卷。
在210名女性参与者中，较高的症状严重程度与失业、独居或有宗教信仰相关。目前正在接受激素治疗的参与者（n = 84）报告，用MDASI测量的症状严重程度与社会支持之间存在显著负相关（p = 0.006）。因此，随着症状严重程度的增加，感知到的社会支持减少。在BCPT评估中，认知功能下降（p < 0.05）、疼痛（p < 0.05）、膀胱功能障碍（p = 0.001）和自我形象降低（p < 0.01）与目前正在接受激素治疗的参与者的社会支持显著负相关。以前未接受过激素治疗的参与者（n = 64），认知功能障碍和膀胱功能障碍与社会支持呈负相关。患有既往心脏或肺部功能障碍以及关节炎的女性报告的症状严重程度在统计学上显著更高，且社会支持感知降低。
识别影响激素治疗症状负担的社会人口统计学变量和共病对于为乳腺癌幸存者提供充分支持至关重要。
